Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
Authors
Keywords
Overall Survival, Bevacizumab, Cetuximab, Panitumumab, Well Supportive Care
Journal
DRUGS
Volume 75, Issue 7, Pages 731-748
Publisher
Springer Nature
Online
2015-04-20
DOI
10.1007/s40265-015-0386-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer
- (2015) Jean-Yves Douillard et al. EUROPEAN JOURNAL OF CANCER
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- O-0030INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306)
- (2014) V. Heinemann et al. ANNALS OF ONCOLOGY
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
- (2014) J. Y. Douillard et al. ANNALS OF ONCOLOGY
- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
- (2014) Lee S. Schwartzberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- European Consensus Conference for external quality assessment in molecular pathology
- (2013) J. H. van Krieken et al. ANNALS OF ONCOLOGY
- Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer
- (2013) M. Peeters et al. ANNALS OF ONCOLOGY
- Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action
- (2013) V. Heinemann et al. CANCER TREATMENT REVIEWS
- Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
- (2013) M. Peeters et al. CLINICAL CANCER RESEARCH
- MC13-0024 Impact of post-progression anti-vascular endothelial growth factor-containing therapy on survival in patients with metastatic colorectal cancer: Data from the PRIME study
- (2013) M. Peeters et al. EUROPEAN JOURNAL OF CANCER
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
- (2012) M. J. Higgins et al. CLINICAL CANCER RESEARCH
- PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
- (2012) Arjun Sood et al. Clinical Colorectal Cancer
- Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients
- (2012) Robert Königsberg et al. ONCOLOGY
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
- (2011) J B Baker et al. BRITISH JOURNAL OF CANCER
- KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective
- (2011) P. R. Blank et al. CLINICAL CANCER RESEARCH
- Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
- (2011) K. Taniguchi et al. CLINICAL CANCER RESEARCH
- Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany
- (2011) Arthi Vijayaraghavan et al. INTERNATIONAL JOURNAL OF CANCER
- First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
- (2011) Claus-Henning Köhne et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Prospective–retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group
- (2011) Scott D Patterson et al. PHARMACOGENOMICS
- Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer
- (2010) C Mao et al. BRITISH JOURNAL OF CANCER
- Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
- (2010) M. Janakiraman et al. CANCER RESEARCH
- Colorectal cancer molecular biology moves into clinical practice
- (2010) C. C. Pritchard et al. GUT
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
- (2010) Mario E. Lacouture et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors
- (2009) E. E. Mancl et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy
- (2009) Ahmad D. Siddiqui et al. ANNALS OF SURGICAL ONCOLOGY
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy
- (2009) A. Chiappa et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
- (2009) Bart Jacobs et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
- (2008) Evangelia Razis et al. BMC CANCER
- Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone
- (2008) Daniel J. Freeman et al. Clinical Colorectal Cancer
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Ras oncogenes: split personalities
- (2008) Antoine E. Karnoub et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Setting future standards for KRAS testing in colorectal cancer
- (2008) Han van Krieken et al. PHARMACOGENOMICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now